AFFYMETRIX (AFFX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX)

AFFX 14.01

0.0%

Apr 1 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (617)	2/3/1998 7:02:00 PM
From: Boyce Burge	Read Replies (1) of 1728

Richard, My take on the HYSQ patent controversy is that it awards them rights to sequencing by hybridization... not an easy stunt as you can imagine. Its hard to believe this would be of great value for pure sequencing, as there are a million tricks needed to make an unknown sequence come out right..... nonetheless HYSQ claims this is what they are doing... who knows how accurate or useful the sequencing really is. BUT, recall that AFFX chips effectively REsequence DNA sequences that are just slightly different from a targeted gene. This resequencing may fall under some claims of the HYSQ patents, though Im sure AFFX argues otherwise. I dont see resequencing as true sequencing, but a judge might differ. Its a worry for AFFX... Caveat...I havent read any patents, just press releases, so there are doubtless other issues as well...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next